Internal Medicine, Rheumatology · Tamarac, FL
NPI
1144219338
Since 2005
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
7431 N University Dr, Suite 300
Tamarac, FL, 33321
Phone (954) 724-5560
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.2M
217,907 services
Medicare patients, 2024
489
Average age 74
Drug cost, 2024
$3.5M
3,796 prescriptions
Company payments, 2025
$1,315
From 13 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Steven C Kimmel was code J0717 (injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)), 108,400 times for 38 patients. In total Steven C Kimmel billed 217,907 services in 78 codes, and Medicare paid $2.2M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-07-13.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 108,400 | 38 | $3.44 | $373K |
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 39,900 | 45 | $8.38 | $334K |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 14,500 | 24 | $9.24 | $134K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 14,325 | 30 | $33.52 | $480K |
| J0897 Injection, denosumab, 1 mg | Office | 5,100 | 62 | $19.64 | $100K |
| 99214 Office E&M - Established | Office | 794 | 373 | $99.73 | $79K |
| 96372 Injection Administration | Office | 717 | 79 | $12.28 | $8,804 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 654 | 304 | $13.32 | $8,713 |
| 99215 Office E&M - Established | Office | 474 | 278 | $150.86 | $72K |
| 96413 Chemotherapy Administration | Office | 423 | 82 | $110.56 | $47K |
| 73110 X-ray - Upper Extremity | Office | 365 | 186 | $32.84 | $12K |
| 73130 X-ray - Upper Extremity | Office | 363 | 186 | $30.12 | $11K |
| 77089 Standard X-ray | Office | 214 | 203 | $32.45 | $6,944 |
| J3489 Injection, zoledronic acid, 1 mg | Office | 210 | 42 | $4.07 | $855 |
| 77080 Standard X-ray | Office | 188 | 188 | $41.68 | $7,836 |
By year: 2022 $2.4M for 217,573 services; 2023 $2.8M for 289,647 services; 2024 $2.2M for 217,907 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 86 | 71 | $8.65 | $744 |
Medicare prescription drug claims, 2024
In 2024, the drug Steven C Kimmel prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 450 prescriptions and refills. In total Steven C Kimmel wrote 3,796 Medicare prescriptions that cost $3.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 450 | 1,134 | 164 | $15K |
| Methotrexate Methotrexate Sodium | 405 | 828 | 152 | $7,009 |
| Prednisone Generic | 332 | 666 | 107 | $3,185 |
| Gabapentin Generic | 174 | 364 | 61 | $1,829 |
| Tizanidine Hcl Generic | 163 | 288 | 59 | $1,132 |
| Orencia Abatacept/Maltose | 141 | 141 | 16 | $655K |
| Folic Acid Generic | 138 | 361 | 52 | $966 |
| Duloxetine Hcl Generic | 126 | 293 | 46 | $2,336 |
| Benlysta Belimumab | 126 | 126 | Under 11 | $375K |
| Alendronate Sodium Generic | 115 | 257 | 47 | $688 |
| Methotrexate Sodium Methotrexate Sodium/Pf | 105 | 188 | 49 | $2,371 |
| Allopurinol Generic | 104 | 296 | 35 | $1,191 |
| Actemra Tocilizumab | 100 | 100 | 12 | $173K |
| Evenity (2 Syringes) Romosozumab-Aqqg | 100 | 100 | 22 | $249K |
| Mycophenolate Mofetil Generic | 93 | 155 | 22 | $8,435 |
Brand drugs: 1,043 claims; generic drugs: 2,672 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Steven C Kimmel $1,315 ($1,280 in general payments such as food, travel and fees and $35.61 for research) from 13 companies. The largest payer was Abbvie Inc. with $427.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 19 | $427 |
| AstraZeneca Pharmaceuticals LP AZN | 4 | $370 |
| UCB, Inc. UCB.BR | 4 | $141 |
| E.R. Squibb & Sons, L.L.C. BMY | 3 | $82.98 |
| GlaxoSmithKline, LLC. GSK | 3 | $74.68 |
| Novartis Pharmaceuticals Corporation NVS | 3 | $61.72 |
| Janssen Biotech, Inc. JNJ | 2 | $49.14 |
| Genzyme Corporation SNY | 1 | $32.64 |
| Pfizer Inc. PFE | 5 | $32.28 |
| Genentech USA, Inc. ROG.SW | 1 | $25 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.